TY - JOUR T1 - The Significance of Molecular Biomarkers on Clinical Survival Outcome Differs Depending on Colon Cancer Sidedness JF - Anticancer Research JO - Anticancer Res SP - 201 LP - 211 DO - 10.21873/anticanres.13941 VL - 40 IS - 1 AU - SHO HIRABAYASHI AU - MASAMICHI HAYASHI AU - GORO NAKAYAMA AU - SHINJI MII AU - NORIFUMI HATTORI AU - HIROSHI TANABE AU - MITSURO KANDA AU - CHIE TANAKA AU - DAISUKE KOBAYASHI AU - SUGURU YAMADA AU - MASAHIKO KOIKE AU - MICHITAKA FUJIWARA AU - MASAHIDE TAKAHASHI AU - YASUHIRO KODERA Y1 - 2020/01/01 UR - http://ar.iiarjournals.org/content/40/1/201.abstract N2 - Background/Aim: This retrospective study focused on the correlation between molecular markers and prognostic outcomes of colon cancer patients depending on sidedness. Materials and Methods: A total of 117 stage I-III colon cancer patients who underwent colectomy were enrolled. Novel methylation markers (KIF1A, PAX5 and VGF) were selected for epigenetic evaluation and p53 and ERCC1 protein expression was examined for the investigation of genetic alterations. Results: High frequency of methylation was observed in 68.2% of right-sided and 39.7% of left-sided colon cancer cases (p=0.004). Abnormal p53 was identified in 52.3% of right-sided and 75.3% of left-sided cases (p=0.015). In right-sided cases, highly methylated genes demonstrated significantly favorable disease-free survival (p=0.049). Regarding left-sided cases, advanced T stage (p=0.028) and abnormal p53 (p=0.028) were revealed to be significant predictive factors of the disease-free survival outcome. Conclusion: Molecular alterations, as significant prognostic factors, might differ depending on the sidedness of colon cancers. ER -